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Results: First, we identified that specific inhibition of PI4K 
IIIα using RNAi increased radiosensitivity in the human cancer 
cell lines we tested. In contrast, inhibition of other isotypes 
did not affect a radiosensitivity of these cancer cell lines. 
Next, in vitro kinase assays showed, simeprevir, a selected 
anti-HCV agent via IC50 assay, inhibited activity of PI4K IIIα in 
a dose-response manner. Pretreatment of simeprevir induced 
discernible downregulation of p-PKC and p-Akt and also 
increased clonogenic survival of U251, BT474, and HepG2 
cells in vitro and also significantly delayed growth of mouse 
tumor xenografts in vivo. Simeprevir caused prolongation of 
γH2AX foci after irradiation, decreased invasion / migration 
and downregulation of PD-L1 expression. 
 
Conclusion: Targeting PI4K IIIα using anti-HCV agent could be 
a viable drug repositioning approach to enhance the 
therapeutic efficacy of radiotherapy for breast cancer, 
glioblastoma and hepatoma. (Work supported by grant 
#2013R1A1A2074531 from the Ministry of Science, ICT & 
Future Planning to Kim IA) 
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Purpose or Objective: To investigate serial changes of tumor 
hypoxia in response to a single high dose irradiation by 
various clinical and pre-clinical methods in order to propose 
an optimal fractionation schedule for stereotactic ablative 
radiotherapy (SABR) 
 
Material and Methods: Syngeneic Lewis lung carcinomas 
were grown either orthotopically or subcutaneously in 
C57BL/6 mice and were irradiated with a single dose of 15 Gy 
to mimic SABR used in the clinic. Serial [18F]-misonidazole 
(F-MISO) positron emission tomography (PET) imaging, 
pimonidazole FACS analyses, hypoxia-responsive element 
(HRE)-driven bioluminescence, and Hoechst 33342 perfusion 
were performed before irradiation (d-1), at 6 hours (d0), 2 
(d2), and 6 days (d6) after irradiation for both subcutaneous 
and orthotopic lung tumors. For F-MISO, scan was performed 
2 hr after the intravenous injection of F-MISO probe and the 
tumor-to-brain ratio (TBR) was analyzed.  
 
Results: We observed that hypoxic signals were too low to 
quantitate for orthotopic tumors by F-MISO PET or HRE-driven 
bioluminescence imaging. In subcutaneous tumors TBR values 
were 2.87 ± 0.483 at d-1, 1.67 ± 0.116 at d0, 2.92 ± 0.334 at 
d2, and 2.13 ± 0.385 at d6, indicating that tumor hypoxia was 
decreased immediately after irradiation and returned to the 
pretreatment levels at d2, followed by a slight decrease by 
d6 post-radiation. Pimonidazole analysis also revealed similar 
patterns. By using Hoechst 33342 vascular perfusion dye and 
CD31 co-immunostaining, we found that there was a rapid 
and transient vascular collapse, which may have resulted in 
poor intratumoral perfusion of F-MISO PET tracer or 
pimonidazole delivered at d0 leading to decreased hypoxic 




Fig. 1. Temporal changes in tumor hypoxia for subcutaneous 
tumors by F-MISO PET imaging. (A) Representative PET 
images demonstrating F-MISO uptake in subcutaneous tumor. 
Arrows indicate the tumor position. (B) A graph showing TBR 
values for an individual animal. (C) A graph showing the mean 
± s.e.m. of TBR values (n = 5).  
 
Conclusion: We found tumor hypoxia levels to be returned to 
the pretreatment levels by 2 days after irradiation, hence 
supporting the current fractionation intervals of SABR being 
given at least 2 days. Our results also indicate that SABR may 
produce a rapid but reversible vascular collapse in tumors. 
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Purpose or Objective: In previous study we showed that 
γH2AX assay in ex vivo irradiated tumour samples collected 
from cancer patients of various types correlates with known 
differences in radioresponsiveness. In the present study we 
aimed to apply the assay in a panel of prostate tumour 
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specimens to investigate whether it could allow 
discrimination of sensitive and resistant tumours of the same 
type. In addition we aimed to further explore the robustness 
of the method via investigating the potential impact of the 
tumour sampling on the reproducibility of the results. 
 
Material and Methods: Tumour biopsies from prostate cancer 
patients undergone radical prostatectomy were cultivated in 
media for 24 h before irradiation (IR) with single doses and 
fixed 24 h post IR. The microenvironmental parameters were 
determined by addition of BrdU (perfusion) and Pimonidazole 
(hypoxia) to media prior to IR. Histological sections of 
previously paraffin-embedded material were stained for 
γH2AX and the foci were evaluated in viable, well 
oxygenated tumour areas. To investigate the heterogeneity 
of radiation response among the different patients, biopsies 
were irradiated with graded single doses (0, 2, 4, 6, 8 Gy) 
while to determine the intratumoural sampling variability, 
biopsies from different tumour locations were irradiated with 
single dose of 4 Gy. 
 
Results: In all the 15 patients currently analyzed we 
observed a linear dose-response of residual γH2AX foci. The 
slope of the dose-response expressed high heterogeneity 
among the different patients (slope values range: 0.83-2.27). 
Using the slope of the foci dose-response as a parameter of 
tumour radiosensitivity we could determine 3 patients 
subgroups, namely resistant, with slope values lower than the 
25th percentile of the slope values distribution (<1.1); 
moderate, with slope values between the 25 and 75th 
percentile and sensitive, with slope values above the 75th 
percentile (>1.8). These results are consistent with previously 
observed slope values for very sensitive (e.g. seminoma, 
slope value >2) and resistant (e.g. GBM, slope value ~1) 
tumour types. ANOVA analysis of the residual foci values post 
4 Gy IR evaluated in tumour cells form different parts of the 
same tumour revealed no significant differences in the foci 
value distributions. 
 
Conclusion: We herein show for the first time that the γH2AX 
ex vivo assay is clinically feasible and able to detect 
differences in cellular radiation sensitivity among patients 
with the same tumour type. Our results suggest that 
intratumoural heterogeneity (potential source of sampling 
error) do not significantly affect the results of the assay. 
Taken together, this assay has a promising potential for 
individualized radiation oncology and prospective validation 
in different tumour types in relation to known tumour 
characteristics and patient’s outcome is warranted. 
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Purpose or Objective: The aim of the project is to present 
an in vitro 3D cellular platform capable of measuring 
radiation-induced cell damage at the cellular scale, enabling 
high-resolution image capture of cell response along the 
proton depth dose.  
 
Material and Methods: A 3D cancer model of dimensions 17 
mm x 17 mm x 5 mm (L x W x H) was developed for proton 
irradiation. The model comprises 1 million uniform 
distributed HT29 colon cancer cells within a type 1 collagen 
scaffold. The model was irradiated with 62 MeV proton 
spread out Bragg peak (SOBP) of 10 mm width. Samples were 
fixed after irradiation, set within agarose gel, processed via 
vibratome to 400 nm thickness slices, stained with markers 
for apoptosis (Caspase-3), DNA double strand breaks (53BP1) 
and hypoxia (CA9). 
 
Results: Alamar blue assay proves the cell metabolism can 
maintain 1-5 days depending on seeding density. The cancer 
cells invade into stroma, form spheroid and show paracrine 
activity (vascular endothelial growth factor and epidermal 
growth factor receptor expression) and hypoxia gradients in 
3D model. The measurement of DNA double strand breaks is 
achievable in 2D fluorescent microscopy but less easily 
resolvable in 3D imaging. The level of cell apoptosis along 
SOBP can be imaged and correlated to the actual position and 
dose. Figure below shows 1 million HT29 3D models are 
irradiated by 5Gy dose and fixed 24 hour after irradiation. 




Conclusion: In this novel methodology of sample processing 
and well-controlled coordination system, correlation between 
the cell response of the 3D cancer model and proton dose 
distribution was possible. The fluorescent images show a 
clear difference in cell apoptosis signal response with depth 
dose, and in the 3D samples we could image a hypoxia 
gradient. Further work is underway to model LET within the 
3D cancer model to be linked to cell response parameters, 
and to repeat the experiment under x-ray irradiation. 
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Purpose or Objective: Late radiation enteropathy affects 
20% of prostate cancer survivors. Inflammatory processes may 
relate to its occurrence. We aimed to assess differences in 
the levels of intestinal mucosa cytokines between patients 
with side-effects after pelvic radiotherapy and healthy 
controls. 
 
Material and Methods: Patients with GI symptoms developing 
after prostate radiotherapy and undergoing colonoscopy were 
recruited for this study. Controls were patients undergoing 
colonoscopy for polyp surveillance. All participants were free 
of bowel cancer. Colonoscopy was performed after standard 
preparation of the bowel with citramag and senna or Kleen 
prep. Biopsies were obtained for cytokine characterization 
and pathologic assessment as follows (Fig.1): 
- (1) Two endoscopic directed biopsies were taken from an 
area where mucosal radiation lesion was present; if no 
mucosal change was obvious, biopsies were taken from the 
anterior rectal wall.  
- (2) A second pair of biopsies was taken from normal looking 
mucosa as close as possible to the previous sampling site. 
